![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » J&J’s Teclistamab Wins FDA Breakthrough Therapy Status
J&J’s Teclistamab Wins FDA Breakthrough Therapy Status
![Breakthrough Status](https://www.fdanews.com/ext/resources/test/Device_Images6/Breakthrough-Status.gif?t=1620169812&width=430)
June 2, 2021
Johnson & Johnson’s (J&J) teclistamab has secured Breakthrough Therapy designation from the FDA as a treatment for relapsed or refractory multiple myeloma.
The bispecific antibody works by targeting both the B-cell maturation antigen and CD3 receptors to induce the killing of tumor cells.
J&J said the designation was supported by promising phase 1 data that will be presented June 8 at the 2021 American Society of Clinical Oncology Annual Meeting.
The drug received a Priority Medicine designation from the European Medicines Agency earlier this year.
Upcoming Events
-
21Oct